Analysis of the transforming growth factor-β1 (TGF-β1) codon 25 gene polymorphism by LightCycler-analysis in patients with chronic hepatitis C infection

DNA polymorphisms and response to treatment in patients with chronic hepatitis C: Results from the HALT-C trial

“…Because advanced fibrosis has been associated with several of the SNPs that we studied [17][18][19][20]27] and with reduced response to antiviral therapy [22], fibrosis stage was a potential confounder in our analysis of response to interferon therapy. We examined host genotype results for their relationship to mean Ishak fibrosis score and fibrosis progression rate among all subjects for whom these data were available (fibrosis score, n = 1128; fibrosis rate, n = 1063) as well as in the 774 subjects participating in the SVR analysis.…”

“…The Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial is an NIH-sponsored clinical trial designed to improve the management and outcomes for patients with difficult-to-cure, advanced chronic hepatitis C. As part of an ancillary study of the HALT-C trial, we carried out genetic testing of a series of candidate genetic variations which had been reported to be associated with either response to interferon-based therapy [7][8][9][10][11][12][13][14][15][16] or with risk of developing hepatic fibrosis [17][18][19][20], which is itself a predictor of therapeutic response. Studying these genetic variations in the HALT-C trial presents an opportunity to assess whether previously reported host genetic factors predict response to treatment with pegylated interferon plus ribavirin among patients who previously failed to respond to interferon-based treatment.…”

Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis

“…71 The effect on fibrosis progression rate in chronic hepatitis C has been less clear. [71][72][73] The role of TGF␤ 1 polymorphisms in hemochromatosis has been investigated in one study. 56 Counterintuitively, the genotype associated with greater TGF␤ 1 production was not seen more frequently in cirrhotic patients, and, instead, those with the Arg/Pro or Pro/Pro genotypes (lower TGF␤ 1 production) developed cirrhosis at a younger age than those with the Arg/Arg genotype.…”

Plasmid-Based Expression Technology Using Growth Hormone Releasing Hormone: A Novel Method for Physiologically Stimulating Long-Term Growth Hormone Secretion

“…For instance, it is known that a leucine to proline substitution in the neuropeptide Y (NPY) signal results in significantly lower plasma NPY levels [58], and that the polymorphism at position 25 of the gene that encodes for transforming growth factor-1 (TGF-1), which changes the amino acid sequence of the signal peptide sequence (arginine to proline), causes a variation in TGF-1 production. In patients with severe hepatic fibrosis, the Pro25 allele is twice as frequent compared to patients with mild fibrosis [59].…”